Skip to main content
Publications
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Ilomaki J, Bell JS, Chan EW, Tolppanen A-M, Luo H, Wei L, Lai EC, Shin J-U, De Paoli G, Pajouheshnia R, Ho FK, Reynolds L, Lau KK, Crystal S, Lau WCY, Man KKC, Brauer R, Chan AYL, Shen C-Y, Kim JH, Lum TYS, Hartikainen S, Koponen M, Rooke E, Bazelier M, Klungel O, Setoguchi S, Pell JP, Cook S, Wong ICK. Application of healthcare 'big data' in CNS drug research: the example of the neurological and mental health global epidemiology network (NeuroGEN). CNS Drugs. 2020 Sep;34(9):897-913. doi: 10.1007/s40263-020-00742-4
Pladevall-Vila M, Pottegard A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hagg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortes J, Aguado J, Perlemuter G, Falissard B, Castellsague J, Jacquot E, Deltour N, Perez-Gutthann S. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case-control study using automated health data sources. CNS Drugs. 2019 Apr;33(4):383-95. doi: 10.1007/s40263-019-00611-9
Lupo PJ, Danysh HE, Plon SE, Curtin K, Malkin D, Hettmer S, Hawkins DS, Skapek SX, Spector LG, Papworth K, Melin B, Erhardt EB, Grufferman S, Schiffman JD. Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med. 2015 May;4(5):781-90. doi: 10.1002/cam4.448